Key statistics
On Tuesday, Eton Pharmaceuticals Inc (ETON:NMQ) closed at 17.45, -24.13% below its 52-week high of 23.00, set on Sep 30, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 17.73 |
|---|---|
| High | 18.08 |
| Low | 17.10 |
| Bid | 17.02 |
| Offer | 18.20 |
| Previous close | 18.15 |
| Average volume | 368.16k |
|---|---|
| Shares outstanding | 26.82m |
| Free float | 25.61m |
| P/E (TTM) | -- |
| Market cap | 486.74m USD |
| EPS (TTM) | -0.2491 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
- Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
- Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
- Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
- Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
- Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
- Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
- Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
- Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
- Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
- Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
More ▼
